Actuate Therapeutics Features Post-Hoc Efficacy And Biomarker Analyses From Randomized Phase 2 Study, Along With Clinical Data From Phase 2 Study Of Elraglusib In Combination With FFX And TGF-Β Inhibitor Losartan In mPDAC Patients, At 2026 ASCO

뉴스 본문을 불러오고 있어요.

Actuate Therapeutics Features Post-Hoc Efficacy And Biomarker Analyses From Randomized Phase 2 Study, Along With Clinical Data From Phase 2 Study Of Elraglusib In Combination With FFX And TGF-Β Inhibitor Losartan In mPDAC Patients, At 2026 ASCO | 웨이프 WAPE

Actuate Therapeutics Features Post-Hoc Efficacy And Biomarker Analyses From Randomized Phase 2 Study, Along With Clinical Data From Phase 2 Study Of Elraglusib In Combination With FFX And TGF-Β Inhibitor Losartan In mPDAC Patients, At 2026 ASCO

기사 요약

관련 종목

댓글 —